Canopy Growth Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CGC research report →
Range $8 – $27.85
Price Chart
About the company
Canopy Growth Corporation, through its various operating units, is actively involved in the cultivation, marketing, and distribution of cannabis and hemp-derived products. These offerings serve both recreational consumers and medical patients across key markets including Canada, the United States, and Germany. The company's business activities are structured into two main divisions: its global cannabis operations and its diverse portfolio of other consumer goods.
- CEO
- Luc Mongeau
- IPO
- 2014
- Employees
- 1,128
- HQ
- Smiths Falls, ON, CA
Get TickerSpark's AI analysis on CGC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $180.77M
- P/E
- -0.83
- PEG
- -0.01
- P/S
- 0.92
- P/B
- 0.41
- EV/EBITDA
- -4.23
- Div Yield
- 0.00%
- Gross Margin
- 21.40%
- Op Margin
- -47.18%
- Net Margin
- -89.20%
- ROE
- -39.36%
- ROIC
- -15.40%
Latest fiscal year · YoY change
- Revenue
- $284.60M+5.8%
- Gross Profit
- $69.67M-12.4%
- Op Income
- $-73,105,000
- Net Income
- $-262,908,000+56.0%
- EPS
- $-0.88+84.1%
- OCF Growth
- +61.5%
- FCF Growth
- +60.6%
- 52W High
- $2.38
- 52W Low
- $0.43
- 50D MA
- $0.75
- 200D MA
- $0.96
- Beta
- 2.41
- RSI (14)
- 19
- Avg Volume
- 2.59M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Canopy Growth posted 22% revenue growth and a smaller adjusted EBITDA loss in Q2, with management pointing to international expansion, better cultivation, and cost cuts as the main drivers toward profitability.· November 6, 2026
- Consolidated net revenue rose 22% year over year to $81.4 million, led by cannabis revenue growth of 30% to $66.2 million.
- International cannabis was the standout, with revenue up 141% year over year and 28% sequentially to $12.3 million.
- Adjusted EBITDA loss narrowed to $2.9 million, and management said the company remains on track to reach positive adjusted EBITDA in the second half of fiscal 2027.
- Gross margin held at 31% in Q2 despite the absence of the Q1 U.S. tariff refund, while SG&A fell about $5 million sequentially.
- Cash and short-term investments were $320 million, and the company said it has not used its ATM since December 2025.
Canopy reported Q2 fiscal 2027 consolidated net revenue of $81.4 million, up 22% year over year. Cannabis revenue increased 30% to $66.2 million, with international cannabis up 141% year over year to $12.3 million, Canada Medical up 18% to $25.8 million, Canada Adult Use up 17% to $21.8 million, and Storz & Bickel revenue down 44% year over year to $50.1 million. Consolidated gross margin was 31% in the quarter, versus 33% a year earlier, and adjusted EBITDA loss was $2.9 million, an improvement of $400 thousand from Q1. Free cash outflow improved by $3.7 million year over year to $15.6 million, and cash plus short-term investments were $320 million as of September 30, 2026. Management said it remains on track to deliver positive adjusted EBITDA in the second half of fiscal 2027, with stronger seasonality expected in Q3 and cultivation/margin benefits expected later in fiscal 2027 and into fiscal 2028.
Luc Mongeau struck an optimistic tone and framed the quarter as evidence that the company’s operating changes are starting to show up in results. He emphasized international growth, the EU GMP end-to-end supply chain, and improving cultivation at Kincardine as the main strategic levers, while also highlighting Canada Adult Use brand momentum and a more focused Germany/Europe commercial push. He repeatedly said the biggest P&L impact will come from better flower yields and a stronger supply chain, with full benefits expected later in fiscal 2027 and into fiscal 2028.
Thomas Carlton Stewart highlighted disciplined execution on both growth and costs. He cited 22% year-over-year revenue growth to $81.4 million, gross margin of 31%, a $2.9 million adjusted EBITDA loss, and about $5 million of sequential SG&A reduction, while noting the loss improved even without the Q1 tariff refund. He also pointed to $320 million of cash and short-term investments, $15.6 million of free cash outflow in the quarter, and said the company has not sold shares through its ATM since December 2025; management would use the ATM selectively for strategic opportunities, including M&A.
Analysts pressed management on the timing of EBITDA profitability, the margin profile into fiscal 2028, and when cultivation upgrades would show up in the P&L. Management said the back half of fiscal 2027 should be stronger, helped by Storz & Bickel seasonality, but that the cultivation transformation and supply-chain streamlining will mostly affect results toward the end of fiscal 2027 and more fully in fiscal 2028. In Europe, management said the Smiths Falls EU GMP certification creates a path to add more product categories, and they were confident in Germany and Poland because the brand and genetics resonate when product is in stock. They also said the recently announced Canadian budget changes would make life easier for LPs and improve access to quality flower.
The positive case is that revenue is growing across most of the business while losses and SG&A are moving in the right direction. Management believes international cannabis, better cultivation yields, and new EU GMP capabilities can expand both sales and margins over time. With $320 million of liquidity and no recent ATM usage, the company says it has runway to fund growth and selective M&A.
The main risk is that profitability still depends on execution that has not yet fully shown up in the numbers, especially cultivation improvements that management says will only hit the P&L later in fiscal 2027 and fiscal 2028. Storz & Bickel revenue fell 44% year over year, and management said the business is still dealing with consumer spending weakness and market variability. Gross margin also remains pressured versus last year by the Veteran Affairs Canada reimbursement cap, and management acknowledged Canopy is not yet a best-in-class cost grower.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 423.35M
- Float Shares
- 422.41M
of shares held by institutions
234 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CGC, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tidal Investments LLC | 8.62M | ▼ 572.09K |
| Morgan Stanley | 2.22M | ▲ 270.71K |
| Lazard Asset Management LLC | 1.79M | ▼ 55.23K |
| Goldman Sachs Group Inc | 1.34M | ▲ 36.90K |
| Ubs Group AG | 1.09M | ▼ 309.85K |
| Susquehanna International Group, Llp | 1.09M | ▼ 133.83K |
| National Bank Of Canada | 835.81K | ▼ 22.65K |
| Sbi Securities Co., Ltd. | 711.68K | ▲ 28.96K |
| Td Asset Management Inc | 684.23K | ▼ 2.40K |
| Sig North Trading, Ulc | 618.17K | ▲ 152.68K |
| Hrt Financial LP | 577.23K | ▼ 137.85K |
| Jane Street Group, LLC | 552.00K | ▼ 1.01M |
Held by 17 ETFs
Biggest fund positions in CGC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 28, 26 | Yanofsky Theresa | sell | 14,920 |
| Sep 28, 26 | Lazzarato David Angelo | sell | 22,380 |
| Sep 28, 26 | BAYERN JOSEPH | sell | 3,096 |
| Sep 28, 26 | ATKINS M SHAN | sell | 3,096 |
| Sep 17, 26 | Stewart Thomas Carlton | sell | 25,755 |
| Aug 24, 26 | Gedeon Christelle | sell | 13,344 |
| Aug 24, 26 | Stewart Thomas Carlton | sell | 2,231 |
| Jun 26, 26 | BAYERN JOSEPH | sell | 3,197 |
| Jun 26, 26 | Yanofsky Theresa | sell | 15,054 |
| Jun 26, 26 | ATKINS M SHAN | sell | 3,197 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CGC coverage
Recent articles, reports, and earnings notes.
No research on CGC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CGC report →Cannabis Stock CGC Loses 26% in a Month: Should You Buy the Dip?
zacks.com · Nov 18
Investors Heavily Search Canopy Growth Corporation (CGC): Here is What You Need to Know
zacks.com · Nov 12
Canopy Growth Corporation: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 7
Canopy Growth Corporation (WEED:CA) Q2 2027 Earnings Call Transcript
seekingalpha.com · Nov 6
Canopy Growth Q2 Earnings Call Highlights
marketbeat.com · Nov 6
Canopy Growth Corporation (CGC) Reports Q2 Loss, Lags Revenue Estimates
zacks.com · Nov 6
Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets Cannabis
businesswire.com · Nov 6
Canopy Growth vs. Tilray Brands: Quarterly Revenue Scale and Consistency in Cannabis
fool.com · Oct 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.